{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:41:45Z","timestamp":1780087305733,"version":"3.54.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00108-025-01953-x","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:23:04Z","timestamp":1752236584000},"page":"793-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CAR-T-Zell-Therapie bei reifzelligen B-Zell-Neoplasien\u00a0\u2013 aktueller Einsatz und praktische Erw\u00e4gungen","CAR T-cell therapy of mature B-cell neoplasms\u2014Current use and practical considerations"],"prefix":"10.1007","volume":"66","author":[{"given":"Theresa","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"1953_CR1","unstructured":"Epidemiology of malignant lymphomas in Italy."},{"key":"1953_CR2","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/jco.2009.24.5860","volume":"28","author":"J-F Larouche","year":"2010","unstructured":"Larouche\u00a0J\u2011F, Berger\u00a0F, Chassagne-Cl\u00e9ment\u00a0C, Ffrench\u00a0M, Callet-Bauchu\u00a0E, Sebban\u00a0C, Ghesqui\u00e8res\u00a0H, Broussais-Guillaumot\u00a0F, Salles\u00a0G, Coiffier\u00a0B (2010) Lymphoma Recurrence 5 Years or Later Following Diffuse Large B\u2011Cell Lymphoma: Clinical Characteristics and Outcome. J\u00a0Clin Oncol 28:2094\u20132100. https:\/\/doi.org\/10.1200\/jco.2009.24.5860","journal-title":"J Clin Oncol"},{"key":"1953_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump\u00a0M, Neelapu\u00a0SS, Farooq\u00a0U, Neste\u00a0EVD, Kuruvilla\u00a0J, Westin\u00a0J, Link\u00a0BK, Hay\u00a0A, Cerhan\u00a0JR, Zhu\u00a0L et\u00a0al (2017) Outcomes in refractory diffuse large B\u2011cell lymphoma: results from the international SCHOLAR-1\u00a0study. Blood 130:1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"1953_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/nejmoa2116133","volume":"386","author":"FL Locke","year":"2021","unstructured":"Locke\u00a0FL, Miklos\u00a0DB, Jacobson\u00a0CA, Perales\u00a0M\u2011A, Kersten\u00a0M\u2011J, Oluwole\u00a0OO, Ghobadi\u00a0A, Rapoport\u00a0AP, McGuirk\u00a0J, Pagel\u00a0JM et\u00a0al (2021) Axicabtagene Ciloleucel as Second-Line Therapy for Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 386:640\u2013654. https:\/\/doi.org\/10.1056\/nejmoa2116133","journal-title":"N Engl J Med"},{"key":"1953_CR5","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/jco.2024.42.16_suppl.7013","volume":"42","author":"MK Kamdar","year":"2024","unstructured":"Kamdar\u00a0MK, Solomon\u00a0SR, Arnason\u00a0J, Johnston\u00a0PB, Gla\u00df\u00a0B, Bachanova\u00a0V, Ibrahimi\u00a0S, Mielke\u00a0S, Mutsaers\u00a0P, Hernandez-Ilizaliturri\u00a0FJ et\u00a0al (2024) Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R\/R large B\u2011cell lymphoma (LBCL): 3\u2011year follow-up (FU) from the randomized, phase\u00a03 TRANSFORM study. J\u00a0Clin Oncol 42:7013\u20137013. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.7013","journal-title":"J Clin Oncol"},{"key":"1953_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/nejmoa2116596","volume":"386","author":"MR Bishop","year":"2021","unstructured":"Bishop\u00a0MR, Dickinson\u00a0M, Purtill\u00a0D, Barba\u00a0P, Santoro\u00a0A, Hamad\u00a0N, Kato\u00a0K, Sureda\u00a0A, Greil\u00a0R, Thieblemont\u00a0C et\u00a0al (2021) Second-Line Tisagenlecleucel or Standard Care in Aggressive B\u2011Cell Lymphoma. N\u00a0Engl J Med 386:629\u2013639. https:\/\/doi.org\/10.1056\/nejmoa2116596","journal-title":"N Engl J Med"},{"key":"1953_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/nejmoa1707447","volume":"377","author":"S Tanya","year":"2017","unstructured":"Tanya\u00a0S, Yi\u00a0L et\u00a0al (2017) Axicabtagene Ciloleucel CAR T\u2011Cell Therapy in Refractory Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/nejmoa1707447","journal-title":"N Engl J Med"},{"key":"1953_CR8","unstructured":"B\u00fccklein V, Subklewe M, W\u00f6rmann B on behalf of the DGHO (2025) CAR-T-Zellen \u2013 Management von Nebenwirkungen. Onkopedia-Leitlinie. Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie (DGHO). https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/car-t-zellen-management-von-nebenwirkungen"},{"key":"1953_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson\u00a0JS, Palomba\u00a0ML, Gordon\u00a0LI, Lunning\u00a0MA, Wang\u00a0M, Arnason\u00a0J, Mehta\u00a0A, Purev\u00a0E, Maloney\u00a0DG, Andreadis\u00a0C et\u00a0al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B\u2011cell lymphomas (TRANSCEND NHL 001): a\u00a0multicentre seamless design study. Lancet 396:839\u2013852. https:\/\/doi.org\/10.1016\/s0140-6736(20)31366-0","journal-title":"Lancet"},{"key":"1953_CR10","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar\u00a0M, Solomon\u00a0SR, Arnason\u00a0J, Johnston\u00a0PB, Glass\u00a0B, Bachanova\u00a0V, Ibrahimi\u00a0S, Mielke\u00a0S, Mutsaers\u00a0P, Hernandez-Ilizaliturri\u00a0F et\u00a0al (2022) Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B\u2011cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase\u00a03\u00a0trial. Lancet 399:2294\u20132308. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6","journal-title":"Lancet"},{"key":"1953_CR11","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1182\/blood-2024-200204","volume":"144","author":"JS Abramson","year":"2024","unstructured":"Abramson\u00a0JS, Palomba\u00a0ML, Gordon\u00a0LI, Lunning\u00a0M, Wang\u00a0M, Arnason\u00a0JE, Kamdar\u00a0M, Maloney\u00a0DG, Shadman\u00a0M, Andreadis\u00a0C et\u00a0al (2024) Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R\/R) Large B\u2011Cell Lymphoma (LBCL). Blood 144:3125\u20133125. https:\/\/doi.org\/10.1182\/blood-2024-200204","journal-title":"Blood"},{"key":"1953_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","volume":"380","author":"SJ Schuster","year":"2018","unstructured":"Schuster\u00a0SJ, Bishop\u00a0MR, Tam\u00a0CS, Waller\u00a0EK, Borchmann\u00a0P, McGuirk\u00a0JP, J\u00e4ger\u00a0U, Jaglowski\u00a0S, Andreadis\u00a0C, Westin\u00a0JR et\u00a0al (2018) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/nejmoa1804980","journal-title":"N Engl J Med"},{"key":"1953_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu\u00a0SS, Chavez\u00a0JC, Sehgal\u00a0AR, Epperla\u00a0N, Ulrickson\u00a0M, Bachy\u00a0E, Munshi\u00a0PN, Casulo\u00a0C, Maloney\u00a0DG, de Vos\u00a0S et\u00a0al (2024) Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 143:496\u2013506. https:\/\/doi.org\/10.1182\/blood.2023021243","journal-title":"Blood"},{"key":"1953_CR14","doi-asserted-by":"publisher","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E et al. (2022) Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28:325\u2013332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0","DOI":"10.1038\/s41591-021-01622-0"},{"key":"1953_CR15","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser\u00a0F, Dahiya\u00a0S, Palomba\u00a0ML, Garcia-Sancho\u00a0AM, Ortega\u00a0JLR, Kuruvilla\u00a0J, J\u00e4ger\u00a0U, Cartron\u00a0G, Izutsu\u00a0K, Dreyling\u00a0M et\u00a0al (2024) Lisocabtagene maraleucel in follicular lymphoma: the phase\u00a02 TRANSCEND FL study. Nat Med 30:2199\u20132207. https:\/\/doi.org\/10.1038\/s41591-024-02986-9","journal-title":"Nat Med"},{"key":"1953_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/nejmoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang\u00a0M, Munoz\u00a0J, Goy\u00a0A, Locke\u00a0FL, Jacobson\u00a0CA, Hill\u00a0BT, Timmerman\u00a0JM, Holmes\u00a0H, Jaglowski\u00a0S, Flinn\u00a0IW et\u00a0al (2020) KTE-X19 CAR T\u2011Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N\u00a0Engl J Med 382:1331\u20131342. https:\/\/doi.org\/10.1056\/nejmoa1914347","journal-title":"N Engl J Med"},{"key":"1953_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/jco.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang\u00a0M, Munoz\u00a0J, Goy\u00a0A, Locke\u00a0FL, Jacobson\u00a0CA, Hill\u00a0BT, Timmerman\u00a0JM, Holmes\u00a0H, Jaglowski\u00a0S, Flinn\u00a0IW et\u00a0al (2023) Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2\u00a0Study. J\u00a0Clin Oncol 41:555\u2013567. https:\/\/doi.org\/10.1200\/jco.21.02370","journal-title":"J Clin Oncol"},{"key":"1953_CR18","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno\u00a0JN, Kochenderfer\u00a0JN (2016) Toxicities of chimeric antigen receptor T\u00a0cells: recognition and management. Blood 127:3321\u20133330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751","journal-title":"Blood"},{"key":"1953_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu\u00a0SS, Tummala\u00a0S, Kebriaei\u00a0P, Wierda\u00a0W, Locke\u00a0FL, Lin\u00a0Y, Jain\u00a0N, Daver\u00a0N, Gulbis\u00a0AM, Adkins\u00a0S et\u00a0al (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u201cALL.\u201d. Nat Rev Clin Oncol 15:218\u2013218. https:\/\/doi.org\/10.1038\/nrclinonc.2018.20","journal-title":"Nat Rev Clin Oncol"},{"key":"1953_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee\u00a0DW, Santomasso\u00a0BD, Locke\u00a0FL, Ghobadi\u00a0A, Turtle\u00a0CJ, Brudno\u00a0JN, Maus\u00a0MV, Park\u00a0JH, Mead\u00a0E, Pavletic\u00a0S et\u00a0al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"1953_CR21","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski\u00a0K, Perez\u00a0A, Sesques\u00a0P, Hoster\u00a0E, Berger\u00a0C, Jentzsch\u00a0L, Mougiakakos\u00a0D, Fr\u00f6lich\u00a0L, Ackermann\u00a0J, B\u00fccklein\u00a0V et\u00a0al (2021) CAR-HEMATOTOX: a\u00a0model for CAR T\u2011cell\u2013related hematologic toxicity in relapsed\/refractory large B\u2011cell lymphoma. Blood 138:2499\u20132513. https:\/\/doi.org\/10.1182\/blood.2020010543","journal-title":"Blood"},{"key":"1953_CR22","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1002\/hem3.70062","volume":"9","author":"S Stock","year":"2025","unstructured":"Stock\u00a0S, B\u00fccklein\u00a0VL, Blumenberg\u00a0V, Magno\u00a0G, Emhardt\u00a0A, Holzem\u00a0AME, Santos, dos\u00a0DMC, Schmidt\u00a0C, Grie\u00dfhammer\u00a0S, Fr\u00f6lich\u00a0L et\u00a0al (2025) Prognostic significance of immune reconstitution following CD19 CAR T\u2011cell therapy for relapsed\/refractory B\u2011cell lymphoma. HemaSphere 9:e70062. https:\/\/doi.org\/10.1002\/hem3.70062","journal-title":"HemaSphere"},{"key":"1953_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.2021015209","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge\u00a0WA, Martus\u00a0P, Schmitt\u00a0M, Holtick\u00a0U, Subklewe\u00a0M, von Tresckow\u00a0B, Ayuk\u00a0F, Wagner-Drouet\u00a0EM, Wulf\u00a0GG, Marks\u00a0R et\u00a0al (2022) GLA\/DRST real-world outcome analysis of CAR T\u2011cell therapies for large B\u2011cell lymphoma in Germany. Blood 140:349\u2013358. https:\/\/doi.org\/10.1182\/blood.2021015209","journal-title":"Blood"},{"key":"1953_CR24","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1002\/hem3.54","volume":"8","author":"P Berning","year":"2024","unstructured":"Berning\u00a0P, Shumilov\u00a0E, Maulhardt\u00a0M, Boyadzhiev\u00a0H, Kerkhoff\u00a0A, Call\u00a0S, Reicherts\u00a0C, Saidy\u00a0AO, Aydilek\u00a0E, Hoffmann\u00a0M et\u00a0al (2024) Chimeric antigen receptor-T\u00a0cell therapy shows similar efficacy and toxicity in patients with diffuse large B\u2011cell lymphoma aged 70 and older compared to younger patients: A\u00a0multicenter cohort study. HemaSphere 8:e54. https:\/\/doi.org\/10.1002\/hem3.54","journal-title":"HemaSphere"},{"key":"1953_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ejh.14100","volume":"112","author":"R Puckrin","year":"2024","unstructured":"Puckrin\u00a0R, Jamani\u00a0K, Jimenez-Zepeda\u00a0VH (2024) Long-term survivorship care after CAR-T\u00a0cell therapy. Eur J Haematol 112:41\u201350. https:\/\/doi.org\/10.1111\/ejh.14100","journal-title":"Eur J Haematol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01953-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01953-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01953-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:19:33Z","timestamp":1753445973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01953-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1953"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01953-x","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"24 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Weber und A.\u00a0Burchert geben an, dass kein Interessenkonflikt besteht. M. Subklewe erhielt Forschungsunterst\u00fctzung von Amgen, BMS\/Celgene, Gilead\/Kite, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Roche, Seagen und Takeda; nahm an Referentent\u00e4tigkeiten f\u00fcr AstraZeneca, BMS, Gilead\/Kite, GSK, Janssen, LAWG, Novartis, Pfizer, Roche und Springer Healthcare teil; \u00fcbernahm eine beratende Funktion oder war Mitglied eines Advisory Boards f\u00fcr AbbVie, Amgen, Autolus, AvenCell, BMS, CanCell Therapeutics, Genmab US, Gilead, Ichnos Sciences, Incyte Biosciences, Interius BioTherapeutics, Janssen, Miltenyi Biomedicine, Molecular Partners, Nektar Therapeutics, Novartis, Orbital Therapeutics, Pfizer, Roche, Sanofi, Scare und Takeda; und erhielt Reiseunterst\u00fctzung von Gilead, Pfizer und Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}